RAPT Therapeutics (NASDAQ: RAPT) furnishes J.P. Morgan Healthcare conference presentation

Rhea-AI Filing Summary

RAPT Therapeutics, Inc. filed a current report to let investors know that the company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is providing its conference presentation as Exhibit 99.1, described as a corporate presentation, and making it available for transparency under Regulation FD, which governs fair disclosure of information to investors. The report also clarifies that the presentation and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000167377200016737722026-01-142026-01-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

RAPT Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38997	47-3313701
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
561 Eccles Avenue
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 489-9000

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		RAPT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 14, 2026, RAPT Therapeutics, Inc. (the “Company”) will participate in the 44th Annual J.P. Morgan Healthcare Conference (the “JPM Conference”). A copy of the Company’s presentation materials for the JPM Conference is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			RAPT Therapeutics, Inc.
Date:	January 14, 2026	By:	/s/ Rodney Young
			Rodney Young Chief Financial Officer

FAQ

What did RAPT (RAPT) disclose in this 8-K filing?

RAPT Therapeutics, Inc. disclosed that it will participate in the 44th Annual J.P. Morgan Healthcare Conference and has furnished its related corporate presentation as Exhibit 99.1.

What is included as Exhibit 99.1 in RAPT (RAPT)'s 8-K?

Exhibit 99.1 is identified as a corporate presentation prepared for RAPT Therapeutics, Inc.'s participation in the 44th Annual J.P. Morgan Healthcare Conference.

Is RAPT (RAPT)'s J.P. Morgan conference presentation considered filed with the SEC?

No. The company states that the information in this report, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Will RAPT (RAPT)'s presentation be automatically incorporated into other SEC filings?

No. The filing specifies that the information in this report and Exhibit 99.1 will not be incorporated by reference into other Exchange Act or Securities Act filings unless expressly stated by specific reference.

Which SEC item does RAPT (RAPT) use for this disclosure?

RAPT Therapeutics, Inc. uses Item 7.01, Regulation FD Disclosure, to report its participation in the J.P. Morgan Healthcare Conference and to furnish the associated presentation.

Who signed the RAPT (RAPT) 8-K related to the J.P. Morgan conference?

The 8-K was signed on behalf of RAPT Therapeutics, Inc. by Rodney Young, the company’s Chief Financial Officer.